AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27814869 — intervention group
Group type: COMPARATOR
Intervention: Advice to remain active (control group)
Number of subjects: 60
Study 25357122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog culling
Number of subjects: 1105
Study 25357122 — intervention group
Group type: COMPARATOR
Intervention: Insecticide spraying
Number of subjects: 1105
Study 25357122 — intervention group
Group type: COMPARATOR
Intervention: Combination of spraying and eliminating dogs
Number of subjects: 1105
Study 25357122 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 1105
Study 23837404 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming and weekly iron supplementation for 6 months
Number of subjects: 1190
Study 23837404 — intervention group
Group type: COMPARATOR
Intervention: Placebo for both anthelmintic and iron
Number of subjects: 1190
Study 20649879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral DXA for aortic vascular calcification (VC) measurement
Number of subjects: 44
Study 20649879 — intervention group
Group type: COMPARATOR
Intervention: CT for aortic vascular calcification (VC) measurement
Number of subjects: 44
Study 20649879 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA for lumbar spine BMD measurement
Number of subjects: 44
Study 18069097 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022
Study 18069097 — intervention group
Group type: COMPARATOR
Intervention: Control group (Engerix-B, Prevnar, Hiberix)
Number of subjects: 2022
Study 16380288 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural graded activity programme
Number of subjects: 0
Study 16380288 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 0
Study 12745616 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV initiated after detecting more than 15 periods of nocturnal desaturation/hour by NPO (Group 2)
Number of subjects: 64
Study 12745616 — intervention group
Group type: COMPARATOR
Intervention: NIV initiated after detecting early signs of diurnal respiratory insufficiency (Group 1)
Number of subjects: 64
Study 10933355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5-10 mg daily)
Number of subjects: 617
Study 10933355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study 9024334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic agents (cholinesterase inhibitors)
Number of subjects: 0
Study 9024334 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants, monoamine oxidase‐B inhibitors, cholinesterase inhibitors, anti‐inflammatory agents
Number of subjects: 0
Study 9024334 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions
Number of subjects: 0
Study 9024334 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs that improve cognition
Number of subjects: 0
Study 1316061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg orally 2‐6 hours prior to surgery
Number of subjects: 499
Study 1316061 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 1 g intravenously or intramuscularly 30‐90 minutes preoperatively
Number of subjects: 499
Study 1316061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin concentrations measured in prostate tissue
Number of subjects: 499
Study 1316061 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 499
Study 7462679 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) 0.3 mg/kg
Number of subjects: 8
Study 7462679 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) 0.6 mg/kg
Number of subjects: 8
Study 7462679 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) 0.9 mg/kg
Number of subjects: 8
Study 31129017 — intervention group
Group type: EXPERIMENTAL
Intervention: Latarjet procedure
Number of subjects: 60
Study 31129017 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft transfer (ICBGT)
Number of subjects: 60
Study 31129017 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 28741653 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate syrup 50 mg.kg-1
Number of subjects: 196
Study 28741653 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline spray (control)
Number of subjects: 196
Study 28741653 — intervention group
Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine spray 3 μg.kg-1
Number of subjects: 196
Study 28741653 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate syrup and placebo spray
Number of subjects: 196
Study 25321659 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplements (4.0 g/d eicosapentaenoic acid and 2.0 g/d docosahexaenoic acid)
Number of subjects: 23
Study 25321659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 25321659 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplements
Number of subjects: 23
Study 24099358 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 33
Study 24099358 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 40 mg
Number of subjects: 33
Study 24099358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21717778 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-hot filiform needle puncturing
Number of subjects: 200
Study 21717778 — intervention group
Group type: COMPARATOR
Intervention: Routine filiform needle puncturing
Number of subjects: 200
Study 19303968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous insulin therapy
Number of subjects: 19
Study 19303968 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin treatment
Number of subjects: 19
Study 17309744 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 126
Study 17309744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 126
Study 17217712 — intervention group
Group type: EXPERIMENTAL
Intervention: xuezhikang (1200 mg/d)
Number of subjects: 100
Study 17217712 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 14513420 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy regimen 1
Number of subjects: 0
Study 14513420 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy regimen 2
Number of subjects: 0
Study 14513420 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy regimen 3
Number of subjects: 0
Study 10472873 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of intravaginal misoprostol, 3-hour interval
Number of subjects: 180
Study 10472873 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg of intravaginal misoprostol, 2-hour interval
Number of subjects: 180
Study 10472873 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg of intravaginal misoprostol, 2-hour interval
Number of subjects: 180
Study 10472873 — intervention group
Group type: COMPARATOR
Intervention: 400 microg of intravaginal misoprostol
Number of subjects: 180
Study 10472873 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg of intravaginal misoprostol
Number of subjects: 180
Study 10472873 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg of intravaginal misoprostol
Number of subjects: 180
Study 10472873 — intervention group
Group type: COMPARATOR
Intervention: 400 microg vs 800 microg
Number of subjects: 180
Study 10472873 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg and 800 microg
Number of subjects: 180
Study 8696797 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal abuse, high overall activity level, standing uncomfortably close to the intended victim
Number of subjects: 62
Study 8696797 — intervention group
Group type: COMPARATOR
Intervention: Non-aggressive controls
Number of subjects: 62
Study 1935017 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder subjects
Number of subjects: 82
Study 1935017 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 82
Study 6750781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate
Number of subjects: 22
Study 31595603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 1023
Study 31595603 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermo-coagulation
Number of subjects: 1023
Study 29483065 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based beginners' running intervention delivered via a closed Facebook group (n=41)
Number of subjects: 89
Study 29483065 — intervention group
Group type: COMPARATOR
Intervention: Control group received a hard copy of the running program (n=48)
Number of subjects: 89
Study 29483065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 27262236 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (PIB)
Number of subjects: 838
Study 27262236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 838
Study 27262236 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (PIB) including prediabetes
Number of subjects: 838
Study 27262236 — intervention group
Group type: COMPARATOR
Intervention: Control group including prediabetes
Number of subjects: 838
Study 26029816 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Havrix™, GSK, Belgium)
Number of subjects: 160
Study 26029816 — intervention group
Group type: COMPARATOR
Intervention: Control group (adults aged 20–30 years)
Number of subjects: 160
Study 23796284 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 0
Study 23796284 — intervention group
Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 0
Study 19909979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.2 mg/d)
Number of subjects: 64
Study 19909979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19909979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/d)
Number of subjects: 64
Study 18227107 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies reporting allocation concealment post-CONSORT statement
Number of subjects: 94
Study 18227107 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects in trials with allocation concealment
Number of subjects: 94
Study 18227107 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect size over time
Number of subjects: 94
Study 18227107 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision of studies over time
Number of subjects: 94
Study 15840761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of diazepam
Number of subjects: 180
Study 15840761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 12574578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) at 2.5 ATA for 60 minutes
Number of subjects: 33
Study 12574578 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment at 1.14 ATA
Number of subjects: 33
Study 10094976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 microgram/kg rHuIL-12 (n = 16)
Number of subjects: 60
Study 10094976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microgram/kg rHuIL-12 (n = 14)
Number of subjects: 60
Study 10094976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microgram/kg rHuIL-12 (n = 15)
Number of subjects: 60
Study 10094976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microgram/kg rHuIL-12 (n = 15)
Number of subjects: 60
Study 10094976 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL-12 (all doses)
Number of subjects: 60
Study 10094976 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL-12 (0.5 microgram/kg)
Number of subjects: 60
Study 9050655 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture technique (group 1)
Number of subjects: 69
Study 9050655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh and staples technique (group 2)
Number of subjects: 69
Study 9050655 — intervention group
Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 69
Study 1752017 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.65 MAC or 1.25 MAC
Number of subjects: 25
Study 1752017 — intervention group
Group type: COMPARATOR
Intervention: Desflurane at 0.65 MAC or 1.25 MAC
Number of subjects: 25
Study 7104587 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP
Number of subjects: 21
Study 7104587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31171016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (125 mL taken twice daily for 12 weeks)
Number of subjects: 0
Study 31171016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (125 mL taken twice daily for 12 weeks)
Number of subjects: 0
Study 31171016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 0
Study 27888696 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater walking training
Number of subjects: 34
Study 27888696 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based walking training
Number of subjects: 34
Study 27888696 — intervention group
Group type: COMPARATOR
Intervention: Control group (underwater walking training)
Number of subjects: 34
Study 25348686 — intervention group
Group type: EXPERIMENTAL
Intervention: KingV-Guideless
Number of subjects: 47
Study 25348686 — intervention group
Group type: COMPARATOR
Intervention: AWS
Number of subjects: 47
Study 25348686 — intervention group
Group type: COMPARATOR
Intervention: KingV-Guided
Number of subjects: 47
Study 24130219 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable system (Inion CPS)
Number of subjects: 230
Study 24130219 — intervention group
Group type: COMPARATOR
Intervention: Titanium group (KLS Martin)
Number of subjects: 230
Study 24130219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 230
Study 20934829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g)
Number of subjects: 100
Study 20934829 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular piroxicam (20 mg)
Number of subjects: 100
Study 20934829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 19193505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day)
Number of subjects: 30
Study 19193505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17530948 — intervention group
Group type: EXPERIMENTAL
Intervention: Half squat with vibration (HSV)
Number of subjects: 17
Study 17530948 — intervention group
Group type: COMPARATOR
Intervention: Half squat (HS)
Number of subjects: 17
Study 15357694 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya dietary intervention (2 servings per day)
Number of subjects: 206
Study 15357694 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.2 servings of soya per day)
Number of subjects: 206
Study 11410192 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin insecticide treatment applied to livestock during the malaria transmission seasons.
Number of subjects: 6
Study 11410192 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin insecticide treatment applied to livestock.
Number of subjects: 6
Study 11410192 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin insecticide treatment applied to livestock in a highly endemic settlement.
Number of subjects: 6
Study 9404682 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate treatment with diet only (Group I)
Number of subjects: 38
Study 9404682 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate treatment with oral hypoglycemic agents (OHA) (Group II)
Number of subjects: 38
Study 9404682 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate treatment with insulin (Group III)
Number of subjects: 38
Study 8234998 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin patches (10 mg/day)
Number of subjects: 10
Study 8234998 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with nitroglycerin patches
Number of subjects: 10
Study 8234998 — intervention group
Group type: COMPARATOR
Intervention: Intermittent treatment with nitroglycerin patches
Number of subjects: 10
Study 3548602 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Flexical)
Number of subjects: 17
Study 3548602 — intervention group
Group type: COMPARATOR
Intervention: High dose steroid regimen
Number of subjects: 17
Study 31006876 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 86
Study 31006876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 29477584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 151
Study 29477584 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 151
Study 27798020 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient management with indwelling pleural catheter (IPC) and talc pleurodesis
Number of subjects: 142
Study 27798020 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient management with chest drain and talc pleurodesis
Number of subjects: 142
Study 27798020 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient management with IPC and talc pleurodesis
Number of subjects: 142
Study 25047497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5 mg with ketoconazole (9 doses of 200 mg pretreatment twice daily)
Number of subjects: 24
Study 25047497 — intervention group
Group type: COMPARATOR
Intervention: Lobeglitazone 0.5 mg without ketoconazole
Number of subjects: 24
Study 22418661 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccines
Number of subjects: 1357
Study 22418661 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted vaccines
Number of subjects: 1357
Study 22418661 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 7.5 µg antigen and full dose of MF59
Number of subjects: 1357
Study 19536599 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assistance (da Vinci)
Number of subjects: 34
Study 19536599 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic instruments
Number of subjects: 34
Study 18025250 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (10-week treatment)
Number of subjects: 536
Study 18025250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10-week treatment)
Number of subjects: 536
Study 18025250 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator ratings
Number of subjects: 536
Study 18025250 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report scores
Number of subjects: 536
Study 15884039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 14
Study 15884039 — intervention group
Group type: COMPARATOR
Intervention: Control nonacupuncture protocol
Number of subjects: 14
Study 12537199 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 80
Study 11303372 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interleukin-2 (IL-2) therapy, 720,000 IU/kg per dose i.v. in 15 minutes, administered in bolus for 2 weeks with a 1 week rest interval.
Number of subjects: 21
Study 11303372 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interleukin-2 (IL-2) therapy with prior autologous vaccines.
Number of subjects: 21
Study 9175669 — intervention group
Group type: EXPERIMENTAL
Intervention: Threatened preterm delivery group
Number of subjects: 0
Study 9175669 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncomplicated pregnancy)
Number of subjects: 0
Study 1446996 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol treatment for 4 to 6 weeks after a 2-week placebo phase
Number of subjects: 38
Study 1446996 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 38
Study 2870353 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH (1.2 mg/day intranasally)
Number of subjects: 252
Study 2870353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 2870353 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH (after second course in open study)
Number of subjects: 252
Study 2870353 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH
Number of subjects: 252
Study 2870353 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH and human chorionic gonadotropin (before treatment)
Number of subjects: 252
Study 2870353 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 252
Study 30870556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 278
Study 30870556 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 278
Study 28661264 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg once daily for 15 days)
Number of subjects: 120
Study 28661264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study 25617983 — intervention group
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa 20 mg/kg/week
Number of subjects: 13
Study 25617983 — intervention group
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa 40 mg/kg/2 weeks
Number of subjects: 13
Study 25617983 — intervention group
Group type: COMPARATOR
Intervention: standard ERT (alglucosidase alfa 20 mg/kg/2 weeks)
Number of subjects: 13
Study 23884299 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H-MRS)
Number of subjects: 22
Study 23884299 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MRS results
Number of subjects: 22
Study 23884299 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes of MRS results
Number of subjects: 22
Study 23884299 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS
Number of subjects: 22
Study 23884299 — intervention group
Group type: EXPERIMENTAL
Intervention: NAA/Cre
Number of subjects: 22
Study 21708809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA diet
Number of subjects: 657
Study 21708809 — intervention group
Group type: COMPARATOR
Intervention: Standard-DHA diet
Number of subjects: 657
Study 19538690 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder-specific psychotherapies (CBT, interpersonal, family, and group therapies)
Number of subjects: 19